Ruxolitinib Tablets/Jekewei Usage and Dosage Guide

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib) is an oral JAK inhibitor that is widely used to treat immune diseases such as myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). Its usage and dosage need to be individually adjusted according to the condition, weight and blood test results of different patients. Below are recommended dosages and usage guidelines for different conditions.

1. Myelofibrosis (MF):

For patients with myelofibrosis, the dose of ruxolitinib is adjusted based on the patient's platelet count. If the platelet count is between 50-100 x 10^9/L, the recommended dose is 5 mg twice daily; if the platelet count is 100-200 x 10^9/L, the dose is adjusted to 15 mg twice daily; if the platelet count exceeds 200 x 10^9/L, the recommended dose is 20 mg twice daily. Medications should be tailored to the patient's tolerance and doses may be adjusted if necessary to minimize side effects.

2. Polycythemia vera (PV):

For patients with polycythemia vera, the initial recommended dose is 10 mg twice daily. During treatment, if the patient's hemoglobin, white blood cell, and platelet counts are normal and there is no response to treatment, the dose can be increased to 25 mg twice daily to further control symptoms and reduce disease recurrence.

3. Graft versus host disease (GVHD):

For patients with chronicGVHD, the recommended dose is 10 mg twice daily. For patients with acute GVHD, the initial dose is 5 mg twice daily. The dose can be gradually adjusted based on the patient's clinical response, especially changes in blood markers such as neutrophil count (ANC) and platelet count. If a patient's ANC and platelet count do not decrease by 50% or more during the initial stages of treatment, the physician may consider increasing the dose to 10 mg twice daily after at least 3 days of treatment. For patients who respond, the dose can be gradually reduced after 6 months of treatment to reduce the occurrence of side effects.

The dose of ruxolitinib should be adjusted based on the patient's specific condition, weight, blood test results, and drug resistance. Medications can be taken with food or alone. Patients need to undergo regular blood tests during use to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.jakavi.com/